DK2961420T3 - Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom - Google Patents

Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom Download PDF

Info

Publication number
DK2961420T3
DK2961420T3 DK14756991.7T DK14756991T DK2961420T3 DK 2961420 T3 DK2961420 T3 DK 2961420T3 DK 14756991 T DK14756991 T DK 14756991T DK 2961420 T3 DK2961420 T3 DK 2961420T3
Authority
DK
Denmark
Prior art keywords
prevention
compositions
treatment
methods
barth syndrome
Prior art date
Application number
DK14756991.7T
Other languages
Danish (da)
English (en)
Inventor
D Travis Wilson
Mark Bamberger
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Application granted granted Critical
Publication of DK2961420T3 publication Critical patent/DK2961420T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK14756991.7T 2013-03-01 2014-02-28 Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom DK2961420T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361771642P 2013-03-01 2013-03-01
US201361771534P 2013-03-01 2013-03-01
US201361839753P 2013-06-26 2013-06-26
PCT/US2014/019622 WO2014134554A1 (en) 2013-03-01 2014-02-28 Methods and compositions for the prevention or treatment of barth syndrome

Publications (1)

Publication Number Publication Date
DK2961420T3 true DK2961420T3 (da) 2019-10-07

Family

ID=51428869

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14756991.7T DK2961420T3 (da) 2013-03-01 2014-02-28 Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom

Country Status (9)

Country Link
US (5) US9687519B2 (enExample)
EP (2) EP2961420B1 (enExample)
JP (4) JP6518197B2 (enExample)
CN (3) CN115990242A (enExample)
CA (1) CA2916880C (enExample)
DK (1) DK2961420T3 (enExample)
ES (1) ES2750258T3 (enExample)
HU (1) HUE046924T2 (enExample)
WO (1) WO2014134554A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015507611A (ja) * 2011-12-09 2015-03-12 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチドおよびその使用
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
EP3230308B1 (en) 2014-12-12 2019-05-01 University of Washington Methods for treating and preventing cardiomyopathy
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
IL269626B1 (en) 2017-04-05 2025-10-01 Stealth Biotherapeutics Corp Crystalline salt forms of boc–d–arg–dmt–lys–(boc)–phe–nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN113383005A (zh) * 2018-12-18 2021-09-10 隐形生物治疗公司 靶向线粒体疾病的类似物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2003062784A2 (en) 2001-08-06 2003-07-31 Vanderbilt University Apparatus and methods for monitoring the status of a metabolically active cell
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
HUE027110T2 (en) 2003-02-04 2016-08-29 Cornell Res Foundation Inc Use of an aromatic cationic peptide
SI1599216T1 (sl) 2003-02-04 2014-02-28 Cornell Research Foundation, Inc. Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
EP1597276A4 (en) * 2003-02-10 2006-11-29 Autogen Res Pty Ltd Therapeutic molecules
US20070026090A1 (en) 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA2554166C (en) 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
EP2012800A2 (en) * 2006-04-18 2009-01-14 Cortendo Invest, AB Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
WO2008137035A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
US20090143279A1 (en) 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
CN104056248A (zh) * 2008-02-26 2014-09-24 康奈尔大学 用于防止和治疗急性肾损伤的方法
US20110197294A1 (en) 2008-06-04 2011-08-11 Gottlieb Roberta A Compositions and methods for restoring mitochondrial electron transfer function
CN102171243A (zh) 2008-08-07 2011-08-31 益普生制药股份有限公司 N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
EP3906933A1 (en) 2009-03-20 2021-11-10 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
US20120122957A1 (en) 2009-04-17 2012-05-17 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
WO2010132347A2 (en) 2009-05-11 2010-11-18 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
JP5909182B2 (ja) 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
US8470784B2 (en) * 2009-08-24 2013-06-25 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
JP2013506696A (ja) 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
AU2010339410A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20110172312A1 (en) 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
EP3511012A1 (en) 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
EA201300215A1 (ru) 2010-08-06 2013-07-30 Эдисон Фармасьютикалз, Инк. Лечение митохондриальных болезней нафтохинонами
WO2012019032A1 (en) 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP3108975A1 (en) 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN106039282A (zh) 2011-10-17 2016-10-26 康奈尔大学 芳香族阳离子肽及其用途
CN106822868A (zh) * 2011-10-21 2017-06-13 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
CA2865317A1 (en) 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013126775A1 (en) * 2012-02-23 2013-08-29 Cornell University Aromatic-cationic peptides and uses of same
AU2013329312A1 (en) 2012-10-09 2015-05-28 Massachusetts Institute Of Technology Treatment of age-related and mitochondrial diseases by inhibition of HIF-1 alpha function
BR112015009072A2 (pt) 2012-10-22 2017-07-04 Henry Ford Health Systems métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma
US9687519B2 (en) * 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
WO2014134554A1 (en) 2014-09-04
CN115990242A (zh) 2023-04-21
US20200345803A1 (en) 2020-11-05
JP2021098704A (ja) 2021-07-01
US20210401923A1 (en) 2021-12-30
US11083771B2 (en) 2021-08-10
JP2016511259A (ja) 2016-04-14
US20180147251A1 (en) 2018-05-31
US11771734B2 (en) 2023-10-03
EP2961420B1 (en) 2019-09-11
US20160228487A1 (en) 2016-08-11
JP6918046B2 (ja) 2021-08-11
EP3626252A1 (en) 2020-03-25
JP7381652B2 (ja) 2023-11-15
CN105407906A (zh) 2016-03-16
CA2916880A1 (en) 2014-09-04
CN115990241A (zh) 2023-04-21
US12268724B2 (en) 2025-04-08
ES2750258T3 (es) 2020-03-25
JP2019147815A (ja) 2019-09-05
JP7072692B2 (ja) 2022-05-20
US9687519B2 (en) 2017-06-27
US20240156892A1 (en) 2024-05-16
EP2961420A1 (en) 2016-01-06
EP2961420A4 (en) 2016-08-17
JP6518197B2 (ja) 2019-05-22
JP2022116008A (ja) 2022-08-09
US11083772B2 (en) 2021-08-10
HUE046924T2 (hu) 2020-03-30
CA2916880C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
DK3364993T3 (da) Fremgangsmåder til behandling af angelman syndrom
DK2961420T3 (da) Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK2906698T3 (da) Fremgangsmåde til behandling af alports syndrom
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3693158T3 (da) Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
PL3394259T3 (pl) Kompozycje i sposoby zmniejszania ekspresji tau
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3456333T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelodysplastisk syndrom
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3107902T3 (da) Forbindelser og fremgangsmåder til at hæmme fascin